Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan-Dec:19:17534666251319175.
doi: 10.1177/17534666251319175. Epub 2025 Mar 18.

Adverse effects of biologics used to treat asthma

Andrea Sitek  1 , Sergio E Chiarella  2 , Thanai Pongdee  2
Affiliations
Review

Adverse effects of biologics used to treat asthma

Andrea Sitek et al. Ther Adv Respir Dis. 2025 Jan-Dec.

Abstract

In this review, we discuss the risks and adverse effects reported for the current Food and Drug Association (FDA)-approved biologics used in the management of asthma, including omalizumab, benralizumab, dupilumab, mepolizumab, reslizumab, and tezepelumab. Our review focuses on the risk of hypersensitivity reactions, infection, and malignancy. Where relevant, we have included information regarding the risk of cardiovascular disease and eosinophilia, and we have included specific information regarding vaccine use among patients receiving the above biologics. We also review currently available data regarding the use of biologics in the context of pregnancy. Our goal is to provide a comprehensive resource for providers utilizing these agents, so that they may adequately counsel patients about the risks of therapy and identify adverse events if they occur.

Keywords: adverse events; asthma; biologics; risks; safety.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest.

References

    1. McGregor MC, Krings JG, Nair P, et al.. Role of biologics in asthma. Am J Respir Crit Care Med 2019; 199(4): 433–445. - PMC - PubMed
    1. Kyriakopoulos C, Gogali A, Markozannes G, et al.. Biologic agents licensed for severe asthma: a systematic review and meta-analysis of randomised controlled trials. Eur Respir Rev 2024; 33(172): 230238. - PMC - PubMed
    1. Benralizumab (package insert). Gaithersburg, MD: AstraZeneca, 2024.
    1. Tezepelumab-ekko (package insert). Gaithersburg, MD: AstraZeneca, 2024.
    1. Omalizumab (package insert). San Francisco, CA: Genentech, 2024.